Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer.
Davide MelisiDo-Youn OhAntoine HollebecqueEmiliano CalvoAnna VargheseErkut BorazanciTeresa MacarullaValeria MerzCamilla ZecchettoYumin ZhaoIvelina GueorguievaMichael ManLeena GandhiShawn T EstremKarim A BenhadjiMark C LanasaEmin AvsarSusan C GubaRocio Garcia-CarboneroPublished in: Journal for immunotherapy of cancer (2021)
ClinicalTrials.gov identifier: NCT02734160.